North America Colorectal Cancer Diagnostics Market
Market Size in USD Billion
CAGR :
% 
 Forecast Period |
2023 –2030 |
 Market Size (Base Year) |
USD 1,625.27 Million |
 Market Size (Forecast Year) |
USD 3,192.46 Million |
 CAGR |
% |
| Major Markets Players |
North America Colorectal Cancer Diagnostics, By Product Type (Instruments and Consumables & Accessories), Test Type (Stool Examination, Blood Test, Imaging Test, Tumor Markers, Biopsy, and Others), Cancer Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Adenocarcinoma, Colorectal Lymphoma, Gastrointestinal Stromal Tumors, Carcinoid Tumors, and Others), Age Group (Geriatric, Adults, and Pediatric), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Ambulatory Surgical Centers, Academic Institutes, and Others) Industry Trends and Forecast to 2030.
North America Colorectal Cancer Diagnostics Market Analysis and Insights
Increasing North America awareness about colorectal cancer has enhanced the market demand. The rising healthcare expenditure for better health services also contributes to the market's growth. The major market players focus on various service launches and approvals during this crucial period. In addition, the increase in improved diagnostic processes and techniques also contributes to the rising demand for colorectal cancer diagnostics testing.
The North America colorectal cancer diagnostics market is expected to gain market growth in the forecast period of 2023 to 2030. Data Bridge Market Research analyses that the market is growing with a CAGR of 8.8% in the forecast period of 2023 to 2030 and is expected to reach USD 3,192.46 million by 2030 from USD 1,625.27 million in 2022.
|
Report Metric |
Details |
|
Forecast Period |
2023 to 2030 |
|
Base Year |
2022 |
|
Historic Years |
2021 (Customizable to 2020-2016) |
|
Quantitative Units |
Revenue in USD Million |
|
Segments Covered |
By Product Type (Instruments and Consumables & Accessories), Test Type (Stool Examination, Blood Test, Imaging Test, Tumor Markers, Biopsy, and Others), Cancer Stages (Stage 0, Stage I, Stage II, Stage III, and Stage IV), Cancer Type (Adenocarcinoma, Colorectal Lymphoma, Gastrointestinal Stromal Tumors, Carcinoid Tumors, and Others), Age Group (Geriatric, Adults, and Pediatric), End User (Hospitals, Diagnostic Centers, Cancer Research Centers, Ambulatory Surgical Centers, Academic Institutes, and Others). |
|
Countries Covered |
U.S., Canada, and Mexico |
|
Market Players Covered |
F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Illumina, Inc., Quest Diagnostics Incorporated, CANON MEDICAL SYSTEMS CORPORATION., Bio-Rad Laboratories, Inc.,Merck KGaA,, FUJIFILM Corporation, Agilent Technologies, Inc., BD, Siemens Healthcare GmbH, Neusoft Corporation, BioFire Diagnostics, Myriad Genetics Inc., QIAGEN, Hologic, Inc., Time Medical Holding., FONAR Corp., PlexBio, MinFound Medical Systems Co., Ltd, FONAR, Corp.
|
Market Definition of North America Colorectal Cancer Diagnostics Market
Colorectal cancer starts in the colon or the rectum. Depending on where they start, these cancers can also be called colon cancer or rectal cancer. Colon cancer and rectal cancer are often grouped because they have many features in common. Colorectal cancer is a disease in which cells in the colon or rectum grow out of control. Sometimes it is called colon cancer, short. The colon is the large intestine or large bowel. The rectum is the passageway that connects the colon to the anus.
Sometimes abnormal growths, called polyps, form in the colon or rectum. Over time, some polyps may turn into cancer. Screening tests can find polyps so they can be removed before becoming cancer. Screening also helps find colorectal cancer early, when treatment works best.
North America Colorectal Cancer Diagnostics Market Dynamics
This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:
Drivers
-
Growing prevalence of colorectal cancer
Colorectal cancer is sometimes called colon cancer, which is a term that combines colon cancer and rectal cancer, which begins in the rectum. Colon cancer typically affects older adults, though it can happen at any age. It usually begins as small, noncancerous (benign) clumps of cells called polyps forming inside the colon. Over time some of these polyps can become colon cancers.
In 2022, according to the American Cancer Society's (ACS) publication, the number of colorectal cancers in the United States for 2023 was 106,970 new cases of colon cancer, 46,050 new cases of rectal cancer, and overall, the lifetime risk of developing colorectal cancer is about 1 in 23 for men and 1 in 26 for women.
-
Rise in the number of patients suffering from diverticulitis and ulcerative colitis.
Diverticulitis refers to inflammation of the diverticula, which are small pouches that form in the colon lining. Ulcerative colitis (UC) is an inflammatory bowel disease (IBD) where people develop inflammation and ulcers in the lining of the large intestine. Treatment options include antibiotics, a temporary, clear liquid diet, pain relief medication, and surgery to remove part of the colon for a few cases only.
In June 2022, according to the information provided by National Center for Biotechnology Information (NCBI), Ulcerative colitis has an incidence of 9 to 20 cases per 100,000 persons per year. Its prevalence is 156 to 291 cases per 100,000 persons per year. Ulcerative colitis has a bimodal pattern of incidence. The main onset peaks between the age of 15 and 30 years. A second and smaller peak of incidence occurs between the age of 50 and 70 years.
Opportunity
-
Rise in healthcare expenditure for cancer diagnosis and treatment
Healthcare expenditure has increased worldwide as people's disposable income in various countries is increasing. Moreover, government bodies and healthcare organizations are taking the initiative by accelerating healthcare expenditure to meet population requirements. The rise in healthcare expenditure simultaneously helps healthcare settings to improve their treatment facilities on colorectal cancer diagnostics as the disorder has been highly prevalent in recent years.
Also, the strategic initiatives key market players take will provide structural integrity and future opportunities for the colorectal cancer diagnostics market in the forecast period of 2023-2030.
Restraint/Challenge
- Increased cost, safety, and convenience issues
Colorectal cancer is fatal, and the diagnosis process of this type of cancer also has safety issues. It is also not cost-effective. One of the costliest medical disorders to treat North America is cancer. Cancer patients may be hospitalized and receive a variety of therapies, such as surgery, radiation therapy, and various systemic therapy. Health insurance premiums for cancer patients are now more expensive than in the past. In addition, their copayment, deductible, and coinsurance costs are rising.
Post COVID-19 Impact on Colorectal Cancer Diagnostics Market
COVID-19 has positively affected the market. Lockdowns and isolation during pandemics complicate disease management and medication adherence. Hence the use of various treatment drugs has widely increased in the world's population. Hence, the pandemic has effected positively on this market.
Recent Developments
- In August 2022, Bio-Rad Laboratories Inc. completed its acquisition of Curiosity Diagnostics, a Poland-based developer of innovative technology solutions for the medical diagnostic and healthcare markets. This has helped the company to increase its product portfolio and North America presence in the market.
- In January 2022, QIAGEN announced new additions to the growing number of applications for QIAcuity, its ultrasensitive digital PCR (dPCR) platform that has set new standards by using so-called nanoplates to process samples in two hours rather than the five hours required by other systems. This has helped the company to expand its product portfolio in the market and helped the company to increase its overall revenue.
North America Colorectal Cancer Diagnostics Market Scope
The North America colorectal cancer diagnostics market is segmented into product type, test type, cancer type, cancer stages, age group, and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to make strategic decisions to identify core market applications.
Product Type
- Instruments
- Consumables & Accessories
On the basis of product type, the North America colorectal cancer diagnostics market is segmented into instruments, consumables & accessories.
Test Type
- Imaging Test
- Stool Examination
- Tumor Markers
- Biopsy
- Blood Test
- Others
On the basis of test type, the North America colorectal cancer diagnostics market is segmented into stool examination, imaging test, biopsy, blood test, tumor markers, and others.
Cancer Type
- Adenocarcinoma
- Colorectal Lymphoma
- Gastrointestinal Stromal Tumors
- Carcinoid Tumors
- Others
On the basis of cancer type, the North America colorectal cancer diagnostics market is segmented into adenocarcinoma, colorectal lymphoma, gastrointestinal stromal tumors, carcinoid tumors, and others.
Cancer Stages
- Stage 0
- Stage i
- Stage ii
- Stage iii
- Stage iv
On the basis of cancer stages, the North America colorectal cancer diagnostics market is segmented into stage 0, stage I, stage II, stage III, and stage IV.
Age Group
- Geriatric
- Adults
- Pediatric
On the basis of age group, the North America colorectal cancer diagnostics market is segmented into geriatric, adults, and pediatric.
End User
- Hospitals
- Diagnostic Centers
- Cancer Research Centers,
- Ambulatory Surgical Centers,
- Academic Institutes
- Others
On the basis of end users, the North America colorectal cancer diagnostics market is segmented into hospitals, diagnostic centers, cancer research centers, ambulatory surgical centers, academic institutes, and others.
North America Colorectal Cancer Diagnostics Market Regional Analysis/Insights
The colorectal cancer diagnostics market is analyzed, and market size insights and trends are provided by country, product type, test type, cancer type, cancer stages, age group, and end user, as referenced above.
The countries covered in this market report are U.S., Canada, and Mexico.
U.S. dominates the colorectal cancer diagnostics market in North America in terms of market share and revenue and will continue to flourish its dominance during the forecast period. This is due to the region's high prevalence of colorectal cancer, and rapid research development is boosting the market.
The country section of the report also provides individual market-impacting factors and changes in regulations in the market that impact the current and future trends of the market. Data points, such as new and replacement sales, country demographics, disease epidemiology, and import-export tariffs, are some of the major pointers used to forecast the market scenario for individual countries. In addition, the presence and availability of North America brands and their challenges faced due to high competition from local and domestic brands and the impact of sales channels are considered while providing forecast analysis of the country data.
Competitive Landscape and Colorectal Cancer Diagnostics Market Share Analysis
The colorectal cancer diagnostics market competitive landscape provides details of the competitors. Details include company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, North America presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance. The above data points are only related to the companies focus on the colorectal cancer diagnostics market.
Some of the major players operating in the colorectal cancer diagnostics market are F. Hoffmann-La Roche Ltd, Koninklijke Philips N.V., Thermo Fisher Scientific Inc., Illumina, Inc., Quest Diagnostics Incorporated, CANON MEDICAL SYSTEMS CORPORATION., Bio-Rad Laboratories, Inc.,Merck KGaA,, FUJIFILM Corporation, Agilent Technologies, Inc., BD, Siemens Healthcare GmbH, Neusoft Corporation, BioFire Diagnostics, Myriad Genetics Inc., QIAGEN, Hologic, Inc., Time Medical Holding., FONAR Corp., PlexBio, MinFound Medical Systems Co., Ltd, FONAR, Corp.
SKU-
Get online access to the report on the World's First Market Intelligence Cloud
- Interactive Data Analysis Dashboard
- Company Analysis Dashboard for high growth potential opportunities
- Research Analyst Access for customization & queries
- Competitor Analysis with Interactive dashboard
- Latest News, Updates & Trend analysis
- Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PRODUCT TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET END USER COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTER’S FIVE FORCES
4.2 PESTEL ANALYSIS
5 INDUSTRY INSIGHTS:
6 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, REGULATIONS
6.1 REGULATORY SCENARIO IN THE U.S
6.2 REGULATORY SCENARIO IN AUSTRALIA
6.3 REGULATORY SCENARIO IN JAPAN
6.4 REGULATORY SCENARIO IN CHINA
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 GROWING PREVALENCE OF COLORECTAL CANCER
7.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS.
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS
7.2 RESTRAINTS
7.2.1 STRINGENT REGULATORY POLICIES
7.2.2 HIGH COST FOR THE COLORECTAL CANCER TREATMENTS.
7.3 OPPORTUNITIES
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.4 CHALLENGES
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS
8 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE
8.1 OVERVIEW
8.2 INSTRUMENTS
8.2.1 PATHOLOGY-BASED INSTRUMENTS
8.2.1.1 PCR INSTRUMENTS
8.2.1.2 SLIDE STAINING SYSTEMS
8.2.1.3 TISSUE PROCESSING SYSTEMS
8.2.1.4 CELL PROCESSORS
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS
8.2.2 IMAGING INSTRUMENTS
8.2.2.1 ULTRASOUND SYSTEMS
8.2.2.2 CT SYSTEMS
8.2.2.3 MRI SYSTEMS
8.2.2.4 OTHERS
8.2.3 BIOPSY INSTRUMENTS
8.2.4 OTHERS
8.3 CONSUMABLES & ACCESSORIES
8.3.1 KITS
8.3.1.1 PCR KITS
8.3.1.2 DNA POLYMERASE KITS
8.3.1.3 NUCLEIC ACID ISOLATION KITS
8.3.1.4 OTHERS
8.3.2 REAGENTS
8.3.2.1 ASSAYS
8.3.2.2 BUFFERS
8.3.2.3 PRIMERS
8.3.2.4 OTHERS
8.3.3 OTHER CONSUMABLES
9 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE
9.1 OVERVIEW
9.2 STOOL EXAMINATION
9.3 BLOOD TEST
9.3.1 COMPLETE BLOOD COUNT (CBC)
9.3.2 TUMOR MARKER TEST
9.3.3 LIVER ENZYME BLOOD TEST
9.4 IMAGING TEST
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN
9.4.2 MRI
9.4.3 ULTRASOUND
9.4.4 POSITION EMISSION TOMOGRAPHY (PET)
9.4.5 OTHERS
9.5 TUMOR MARKERS
9.5.1 CARCINOEMBRYONIC ANTIGEN (CEA)
9.5.2 CA19-9 BIOMARKER TEST
9.5.3 CA 50 MARKER TEST
9.5.4 OTHERS
9.6 BIOPSY
9.7 OTHERS
10 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES
10.1 OVERVIEW
10.2 STAGE III
10.3 STAGE IV
10.4 STAGE II
10.5 STAGE I
10.6 STAGE 0
11 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP
11.1 OVERVIEW
11.2 GERIATRIC
11.3 ADULTS
11.4 PEDIATRIC
12 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE
12.1 OVERVIEW
12.2 ADENOCARCINOMA
12.3 COLORECTAL LYMPHOMA
12.4 GASTROINTESTINAL STROMAL TUMORS
12.5 CARCINOID TUMORS
12.6 OTHERS
13 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITALS
13.3 DIAGNOSTIC CENTERS
13.4 CANCER RESEARCH CENTERS
13.5 AMBULATORY SURGICAL CENTERS
13.6 ACADEMIC INSTITUTES
13.7 OTHERS
14 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION
14.1 NORTH AMERICA
14.1.1 U.S.
14.1.2 CANADA
14.1.3 MEXICO
15 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE
15.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
16 SWOT ANALYSIS
17 COMPANY PROFILE
17.1 F. HOFFMANN- LA ROCHE LTD
17.1.1 COMPANY SNAPSHOT
17.1.2 REVENUE ANALYSIS
17.1.3 COMPANY SHARE ANALYSIS
17.1.4 PRODUCT PORTFOLIO
17.1.5 RECENT DEVELOPMENT
17.2 KONINKLIJKE PHILIPS N.V.
17.2.1 COMPANY SNAPSHOT
17.2.2 REVENUE ANALYSIS
17.2.3 COMPANY SHARE ANALYSIS
17.2.4 PRODUCT PORTFOLIO
17.2.5 RECENT DEVELOPMENT
17.3 THERMO FISHER SCIENTIFIC INC.
17.3.1 COMPANY SNAPSHOT
17.3.2 REVENUE ANALYSIS
17.3.3 COMPANY SHARE ANALYSIS
17.3.4 PRODUCT PORTFOLIO
17.3.5 RECENT DEVELOPMENT
17.4 ILLUMINA, INC.
17.4.1 COMPANY SNAPSHOT
17.4.2 REVENUE ANALYSIS
17.4.3 COMPANY SHARE ANALYSIS
17.4.4 PRODUCT PORTFOLIO
17.4.5 RECENT DEVELOPMENT
17.5 QUEST DIAGNOSTICS INCORPORATED
17.5.1 COMPANY SNAPSHOT
17.5.2 REVENUE ANALYSIS
17.5.3 COMPANY SHARE ANALYSIS
17.5.4 PRODUCT PORTFOLIO
17.5.5 RECENT DEVELOPMENT
17.6 ABBOTT
17.6.1 COMPANY SNAPSHOT
17.6.2 REVENUE ANALYSIS
17.6.3 PRODUCT PORTFOLIO
17.6.4 RECENT DEVELOPMENT
17.7 AGILENT TECHNOLOGIES, INC.
17.7.1 COMPANY SNAPSHOT
17.7.2 REVENUE ANALYSIS
17.7.3 PRODUCT PORTFOLIO
17.7.4 RECENT DEVELOPMENT
17.8 BD
17.8.1 COMPANY SNAPSHOT
17.8.2 REVENUE ANALYSIS
17.8.3 PRODUCT PORTFOLIO
17.8.4 RECENT DEVELOPMENT
17.9 BEIJING O&D BIOTECH CO., LTD.
17.9.1 COMPANY SNAPSHOT
17.9.2 PRODUCT PORTFOLIO
17.9.3 RECENT DEVELOPMENT
17.1 BIOFIRE DIAGNOSTICS
17.10.1 COMPANY SNAPSHOT
17.10.2 REVENUE ANALYSIS
17.10.3 PRODUCT PORTFOLIO
17.10.4 RECENT DEVELOPMENT
17.11 BIO-RAD LABORATORIES, INC.
17.11.1 COMPANY SNAPSHOT
17.11.2 REVENUE ANALYSIS
17.11.3 PRODUCT PORTFOLIO
17.11.4 RECENT DEVELOPMENT
17.12 CANON MEDICAL SYSTEMS CORPORATION.
17.12.1 COMPANY SNAPSHOT
17.12.2 REVENUE ANALYSIS
17.12.3 PRODUCT PORTFOLIO
17.12.4 RECENT DEVELOPMENT
17.13 FONAR CORP.
17.13.1 COMPANY SNAPSHOT
17.13.2 REVENUE ANALYSIS
17.13.3 PRODUCT PORTFOLIO
17.13.4 RECENT DEVELOPMENT
17.14 FUJIFILM CORPORATION
17.14.1 COMPANY SNAPSHOT
17.14.2 REVENUE ANALYSIS
17.14.3 PRODUCT PORTFOLIO
17.14.4 RECENT DEVELOPMENT
17.15 GE HEALTHCARE.
17.15.1 COMPANY SNAPSHOT
17.15.2 REVENUE ANALYSIS
17.15.3 PRODUCT PORTFOLIO
17.15.4 RECENT DEVELOPMENT
17.16 HOLOGIC, INC.
17.16.1 COMPANY SNAPSHOT
17.16.2 REVENUE ANALYSIS
17.16.3 PRODUCT PORTFOLIO
17.16.4 RECENT DEVELOPMENT
17.17 MEDONICA CO. LTD
17.17.1 COMPANY SNAPSHOT
17.17.2 PRODUCT PORTFOLIO
17.17.3 RECENT DEVELOPMENT
17.18 MERCK KGAA
17.18.1 COMPANY SNAPSHOT
17.18.2 REVENUE ANALYSIS
17.18.3 PRODUCT PORTFOLIO
17.18.4 RECENT DEVELOPMENT
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD
17.19.1 COMPANY SNAPSHOT
17.19.2 PRODUCT PORTFOLIO
17.19.3 RECENT DEVELOPMENT
17.2 MYRIAD GENETICS, INC.
17.20.1 COMPANY SNAPSHOT
17.20.2 REVENUE ANALYSIS
17.20.3 PRODUCT PORTFOLIO
17.20.4 RECENT DEVELOPMENT
17.21 NEUSOFT CORPORATION
17.21.1 COMPANY SNAPSHOT
17.21.2 REVENUE ANALYSIS
17.21.3 PRODUCT PORTFOLIO
17.21.4 RECENT DEVELOPMENT
17.22 PLEXBIO
17.22.1 COMPANY SNAPSHOT
17.22.2 PRODUCT PORTFOLIO
17.22.3 RECENT DEVELOPMENT
17.23 QIAGEN
17.23.1 COMPANY SNAPSHOT
17.23.2 REVENUE ANALYSIS
17.23.3 PRODUCT PORTFOLIO
17.23.4 RECENT DEVELOPMENT
17.24 SIEMENS HEALTHCARE GMBH
17.24.1 COMPANY SNAPSHOT
17.24.2 REVENUE ANALYSIS
17.24.3 1.2.3 PRODUCT PORTFOLIO
17.24.4 RECENT DEVELOPMENT
17.25 STERNMED GMBH
17.25.1 COMPANY SNAPSHOT
17.25.2 PRODUCT PORTFOLIO
17.25.3 RECENT DEVELOPMENT
17.26 TIME MEDICAL HOLDING.
17.26.1 COMPANY SNAPSHOT
17.26.2 PRODUCT PORTFOLIO
17.26.3 RECENT DEVELOPMENT
18 QUESTIONNAIRE
19 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 2 NORTH AMERICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 3 NORTH AMERICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 4 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 5 NORTH AMERICA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 6 NORTH AMERICA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 7 NORTH AMERICA CONSUMABLES AND ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 8 NORTH AMERICA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 9 NORTH AMERICA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 10 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 11 NORTH AMERICA STOOL EXAMINATION IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 12 NORTH AMERICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 13 NORTH AMERICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 14 NORTH AMERICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 15 NORTH AMERICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 16 NORTH AMERICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 17 NORTH AMERICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 18 NORTH AMERICA BIOPSY IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 19 NORTH AMERICA OTHERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 20 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 21 NORTH AMERICA STAGE III IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 22 NORTH AMERICA STAGE IV IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 23 NORTH AMERICA STAGE II IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 24 NORTH AMERICA STAGE I IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 25 NORTH AMERICA STAGE 0 IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 26 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 27 NORTH AMERICA GERIATRIC IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 28 NORTH AMERICA ADULTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 29 NORTH AMERICA PEDIATRIC IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 30 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 31 NORTH AMERICA ADENOCARCINOMA IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 32 NORTH AMERICA COLORECTAL LYMPHOMA IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 33 NORTH AMERICA GASTROINTESTINAL STROMAL TUMORS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 34 NORTH AMERICA CARCINOID TUMORS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 35 NORTH AMERICA OTHERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 36 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 37 NORTH AMERICA HOSPITALS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 38 NORTH AMERICA DIAGNOSTIC CENTERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 39 NORTH AMERICA CANCER RESEARCH CENTERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 40 NORTH AMERICA AMBULATORY SURGICAL CENTERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 41 NORTH AMERICA ACADEMIC INSTITUTES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 42 NORTH AMERICA OTHERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION, 2021-2030 (USD MILLION)
TABLE 43 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2021-2030 (USD MILLION)
TABLE 44 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 45 NORTH AMERICA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 46 NORTH AMERICA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 47 NORTH AMERICA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 48 NORTH AMERICA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 49 NORTH AMERICA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 50 NORTH AMERICA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 51 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 52 NORTH AMERICA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 53 NORTH AMERICA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 54 NORTH AMERICA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 55 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 56 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 57 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 58 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 59 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 60 U.S. INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 61 U.S. PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 62 U.S. IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 63 U.S. CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 64 U.S. KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 65 U.S. REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 66 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 67 U.S. BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 68 U.S. IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 69 U.S. TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 70 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 71 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 72 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 73 U.S. COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 74 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 75 CANADA INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 76 CANADA PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 77 CANADA IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 78 CANADA CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 79 CANADA KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 80 CANADA REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 81 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 82 CANADA BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 83 CANADA IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 84 CANADA TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 85 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 86 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 87 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 88 CANADA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
TABLE 89 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 90 MEXICO INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 91 MEXICO PATHOLOGY-BASED INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 92 MEXICO IMAGING INSTRUMENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 93 MEXICO CONSUMABLES & ACCESSORIES IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 94 MEXICO KITS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 95 MEXICO REAGENTS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2021-2030 (USD MILLION)
TABLE 96 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 97 MEXICO BLOOD TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 98 MEXICO IMAGING TEST IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 99 MEXICO TUMOR MARKERS IN COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE, 2021-2030 (USD MILLION)
TABLE 100 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES, 2021-2030 (USD MILLION)
TABLE 101 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE, 2021-2030 (USD MILLION)
TABLE 102 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP, 2021-2030 (USD MILLION)
TABLE 103 MEXICO COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER, 2021-2030 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 8 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: MARKET END USER COVERAGE GRID
FIGURE 9 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: SEGMENTATION
FIGURE 11 THE INCREASE IN THE AWARENESS ABOUT COLORECTAL CANCER IS EXPECTED TO DRIVE THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET GROWTH IN THE FORECAST PERIOD
FIGURE 12 THE INSTRUMENTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET IN 2023 & 2030
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET
FIGURE 14 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2022
FIGURE 15 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, 2023-2030 (USD MILLION)
FIGURE 16 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, CAGR (2023-2030)
FIGURE 17 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY PRODUCT TYPE, LIFELINE CURVE
FIGURE 18 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2022
FIGURE 19 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, 2023-2030 (USD MILLION)
FIGURE 20 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, CAGR (2023-2030)
FIGURE 21 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY TEST TYPE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2022
FIGURE 23 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, 2023-2030 (USD MILLION)
FIGURE 24 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, CAGR (2023-2030)
FIGURE 25 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER STAGES, LIFELINE CURVE
FIGURE 26 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2022
FIGURE 27 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, 2023-2030 (USD MILLION)
FIGURE 28 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, CAGR (2023-2030)
FIGURE 29 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY AGE GROUP, LIFELINE CURVE
FIGURE 30 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2022
FIGURE 31 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, 2023-2030 (USD MILLION)
FIGURE 32 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, CAGR (2023-2030)
FIGURE 33 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY CANCER TYPE, LIFELINE CURVE
FIGURE 34 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, 2022
FIGURE 35 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, 2023-2030 (USD MILLION)
FIGURE 36 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, CAGR (2023-2030)
FIGURE 37 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: SNAPSHOT (2022)
FIGURE 39 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022)
FIGURE 40 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2023 & 2030)
FIGURE 41 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: BY COUNTRY (2022 & 2030)
FIGURE 42 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: PRODUCT TYPE (2023-2030)
FIGURE 43 NORTH AMERICA COLORECTAL CANCER DIAGNOSTICS MARKET: COMPANY SHARE 2022 (%)
Research Methodology
Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.
The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.
Customization Available
Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.
